Emerging Evidence in Non-Small Cell Lung Cancer
29th Jul 2026, 5:00pm (GMT)
Free, Online
Advancing Care in Relapsed/Refractory Multiple Myeloma | Interactive Roundtable
6th - 7th Aug 2026, 11:00pm (GMT)
Evolving Paradigms in Lung Cancer
14th - 15th Jul 2026, 11:00pm (GMT)
Advancing Care in Relapsed/Refractory Multiple Myeloma: Module 3 Optimizing Treatment Sequencing and use of BCMA BsAb combinations in RRMM
Duration: 25m 17s
11 days ago
Advancing Care in Relapsed/Refractory Multiple Myeloma: Module 2 Preventing Infection-related Morbidity During Continuous BCMA Therapy
Duration: 29m 42s
12 days ago
Advancing Care in Relapsed/Refractory Multiple Myeloma: Module 1 Implementing Outpatient & Hybrid Delivery Pathways
Duration: 17m 10s
Epithelioid Sarcoma QuickBits Diagnosis Tree
The ARIA System Stress Test: Surveillance and Workflow Toolkit
Epithelioid Sarcoma QuickBits Patient SnapShot
From Ideal to Real: Making Guideline-Based Treatment Decisions for Bladder Cancer in Every Care Setting (Combined Modules)
Duration: 1hr 29m 5s
19 days ago
M032 Clinical Snapshot Toolkit 2
Added 29 Jun 2026
M032 Clinical Snapshot Toolkit 1
From Signal to Action: Understanding Biomarkers in Real-World Bladder Cancer Care
Duration: 19m 34s
a month ago
Aligned Care in Bladder Cancer - Module 3: Advanced/Metastatic Urothelial Carcinoma - Systemic Therapy and Follow-Up
Duration: 28m 43s
Aligned Care in Bladder Cancer - Module 2: Muscle-Invasive Bladder Cancer - Curative Intent Pathways
Duration: 25m 58s
Aligned Care in Bladder Cancer - Module 1: High-Risk NMIBC - Treatment Escalation Decisions
Duration: 36m 48s
From Ideal to Real: Making Guideline-Based Treatment Decisions for Bladder Cancer in Every Care Setting
17th - 18th Jun 2026, 11:00pm (GMT)
Série Synergy sur le mCRPC: La résistance aux inhibiteurs de la voie du récepteur des androgènes dans le mCRPC - Infographie
Resistencia al inhibidor de la vía del receptor de andrógenos en el cáncer de próstata resistente a la castración metastásico (CPRCm) - Infografía
mCRPC Synergy-Serie - Resistenz gegen Androgenrezeptor-Signalweg-Inhibitoren (ARPI) bei mCRPC - Infografik
